What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective

Clinical and Experimental Rheumatology

Volumn 19, Issue 6 SUPPL. 25, 2001, Pages

  Hochberg, M C ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

COX 2 selective inhibitor; Nonsteroidal anti inflammatory drug; Osteoarthritis; Rheumatoid arthritis; Ulcer disease

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG USE; GASTROINTESTINAL DISEASE; HEART INFARCTION; HUMAN; HYPOTHESIS; KIDNEY DISEASE; METHODOLOGY; OSTEOARTHRITIS; OUTCOMES RESEARCH; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZATION; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; SYMPTOM; THROMBOCYTE AGGREGATION INHIBITION; THROMBOEMBOLISM; TREATMENT OUTCOME; ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ISOENZYMES; LACTONES; MEMBRANE PROTEINS; MYOCARDIAL INFARCTION; OSTEOARTHRITIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS; RHEUMATOLOGY; STOMACH ULCER; SULFONAMIDES; SULFONES; TREATMENT OUTCOME;

EID: 0034782126     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Nonsteroidal anti-inflammatory drugs
2. EULAR recommendations for the management of knee osteoarthritis: Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)
3. Recommendations for the medical management of osteoarthritis of the hip and knee
4. Non-aspirin, nonsteroidal anti-inflammatory drugs for osteoarthritis of the knee (Cochrane Review)
5. Analgesia and non-aspirin, nonsteroidal anti-inflammatory drugs for osteoarthritis of the hip (Cochrane Review)
6. Meta-analysis of NSAIDs: Contributions of drugs, doses, trial designs, and meta-analytic techniques
7. Review of dose-response studies of NSAIDs in rheumatoid arthritis
8. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs
9. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2
10. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function
11. Effects of nonsteroidal anti-inflammatory drugs on renal function: Focus on cyclooxygenase-2 selective inhibition
12. Renal safety and tolerability of celecoxib, a novel cyclooxygenase (COX)-2 inhibitor
13. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2 specific inhibitors
14. Renal effects of COX-2 selective inhibitors
15. Multiple female reproductive failures in cyclooxygenase-2 deficient mice
16. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding and perforation: An overview of epidemiological studies published in the 1990s
17. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons
18. The epidemiology of myocardial infarction and heart failure among users of nonsteroidal anti-inflammatory drugs
19. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: An underrecognized public health problem
20. Risk of adverse birth outcome and miscarriage in pregnant users of nonsteroidal anti-inflammatory drugs: Population based observational study and case-control study
21. Epidemiological assessment of the safety of conventional nonsteroidal anti-inflammatory drugs
22. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents
23. The future of NSAID therapy: Selective COX-2 inhibitors
24. Scientific rationale for specific inhibition of COX-2
25. Summary of evidence for COX-2 inhibitors
26. Preliminary study of the safety and efficacy of SC-58365, a novel cyclooxygenase 2 inhibitor
27. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial
28. Celecoxib versus diclofenac in the management of osteoarthritis of the knee: A placebo-controlled, randomised, double-blind comparison
29. Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee
30. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomized double-blind comparison
31. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
32. Effect of specific COX-2 inhibition in osteoarthritis of the knee: A 6-week double-blind, placebo-controlled pilot study of rofecoxib
33. Rofecoxib, a new cyclooxygenase-2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: A 6-week and a 1-year trial in patients with osteoarthritis
34. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis
35. Tolerability profiles of rofecoxib (Vioxx)® and Arthrotec®
36. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis
37. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase-2 specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
38. Comparison of the effect of rofecoxib (a cyclo-oxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial
39. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis
40. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
41. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?
42. Analysis of the effect of COX-2 specific inhibitors and recommendations for their use in clinical practice
43. Recommendations for the clinical use of cyclooxygenase-2 specific inhibitors
44. An update on specific COX-2 inhibitors: The COXIBs
45. Pharmacologic therapy of osteoarthritis
46. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis
47. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
48. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations
49. Cyclooxygenase-2-specific inhibitors and cardiorenal function: A randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients
50. Comparative blood pressure effects of rofecoxib, celecoxib, and placebo in patients with osteoarthritis: A randomized controlled trial
51. Rofecoxib provides superior relief of symptoms of osteoarthritis compared to celecoxib
52. Cyclooxygenase inhibition and thrombogenicity
53. Cardiovascular safety profile of rofecoxib: A meta-analysis
54. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers
55. COX-2 specific inhibitors: Is there any benefit of using these agents in patients on low dose aspirin?